Compare ASTRAZENECA PHARMA with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NEULAND LABS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NEULAND LABS ASTRAZENECA PHARMA/
NEULAND LABS
 
P/E (TTM) x 134.4 68.9 195.1% View Chart
P/BV x 37.7 2.5 1,536.1% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ASTRAZENECA PHARMA   NEULAND LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
NEULAND LABS
Mar-20
ASTRAZENECA PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs1,278754 169.6%   
Low Rs883247 356.9%   
Sales per share (Unadj.) Rs228.4594.5 38.4%  
Earnings per share (Unadj.) Rs10.412.6 82.0%  
Cash flow per share (Unadj.) Rs16.337.0 43.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8553.4 17.8%  
Shares outstanding (eoy) m25.0012.83 194.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.8 561.9%   
Avg P/E ratio x104.239.6 263.1%  
P/CF ratio (eoy) x66.413.5 491.4%  
Price / Book Value ratio x10.90.9 1,209.4%  
Dividend payout %015.8 0.0%   
Avg Mkt Cap Rs m27,0086,421 420.6%   
No. of employees `0001.41.3 105.8%   
Total wages/salary Rs m1,5351,236 124.3%   
Avg. sales/employee Rs Th4,210.95,949.4 70.8%   
Avg. wages/employee Rs Th1,132.2963.8 117.5%   
Avg. net profit/employee Rs Th191.1126.4 151.1%   
INCOME DATA
Net Sales Rs m5,7107,627 74.9%  
Other income Rs m12339 315.3%   
Total revenues Rs m5,8337,666 76.1%   
Gross profit Rs m4631,019 45.4%  
Depreciation Rs m147313 47.1%   
Interest Rs m0216 0.0%   
Profit before tax Rs m438529 82.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179367 48.7%   
Profit after tax Rs m259162 159.9%  
Gross profit margin %8.113.4 60.7%  
Effective tax rate %40.869.4 58.9%   
Net profit margin %4.52.1 213.5%  
BALANCE SHEET DATA
Current assets Rs m3,2095,152 62.3%   
Current liabilities Rs m2,0703,576 57.9%   
Net working cap to sales %20.020.7 96.6%  
Current ratio x1.61.4 107.6%  
Inventory Days Days72105 68.8%  
Debtors Days Days3591 38.4%  
Net fixed assets Rs m7903,969 19.9%   
Share capital Rs m50129 38.8%   
"Free" reserves Rs m2,4196,971 34.7%   
Net worth Rs m2,4697,100 34.8%   
Long term debt Rs m0774 0.0%   
Total assets Rs m4,60512,310 37.4%  
Interest coverage xNM3.5-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.6 200.1%   
Return on assets %5.63.1 183.3%  
Return on equity %10.52.3 459.6%  
Return on capital %17.79.5 187.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3005,187 5.8%   
Fx outflow Rs m2,0151,593 126.5%   
Net fx Rs m-1,7153,594 -47.7%   
CASH FLOW
From Operations Rs m88573 15.3%  
From Investments Rs m-94-487 19.2%  
From Financial Activity Rs mNA-55 0.0%  
Net Cashflow Rs m-633 -17.5%  

Share Holding

Indian Promoters % 0.0 36.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 63.7 0.5%  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 63.7 14.3%  
Shareholders   12,856 12,705 101.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 22, 2021 03:36 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS